Supplementary Table S1 from Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach

PDF file - 52 KB, IC50 of 13-197 in different MCL cell lines</p

Supplementary Figures S1-S3 from Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach

PDF file - 633 KB, Figure S1: Effect of 13-197 on the viability of normal B (nB) cells. Figure S2: Constitutive activation of NF-kB and mTOR pathway in different MCL cells. Figure S3: Effect of 13-197 on the activation of mTOR pathway molecules.</p

Isatin Derived Spirocyclic Analogues with α‑Methylene-γ-butyrolactone as Anticancer Agents: A Structure–Activity Relationship Study

Design, synthesis, and evaluation of α-methylene-γ-butyrolactone analogues and their evaluation as anticancer agents is described. SAR identified a spirocyclic analogue <b>19</b> that inhibited TNFα-induced NF-κB activity, cancer cell growth and tumor growth in an ovarian cancer model. A second iteration of synthesis and screening identified <b>29</b> which inhibited cancer cell growth with low-μM potency. Our data suggest that an isatin-derived spirocyclic α-methylene-γ-butyrolactone is a suitable core for optimization to identify novel anticancer agents

Supplementary Tables 1 - 5 from Targeting the NF-κB and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKKβ for Pancreas Cancer Therapy

PDF file - 53K, Table S1: Pancreatic cancer cell growth inhibition by 13-197; Table S2: % Neutrophils upon prolonged treatment with 13-197; Table S3: Metastases in mice treated with 13-197; Table S4: Immunohistochemical analysis of tumor samples; Table S5: Inflammation and Necrosis in tumor tissues</p